Start here
What I like about roflumilast is how few caveats come with it — once a day, no skin thinning, no boxed warning, no cap on how much skin you treat or how long you use it. For psoriasis in the armpits, groin or under the breasts, where I have spent years rationing steroids, that changes the conversation. It is cosmetically good too, which matters when you treat visible skin for years.
The honest limits: it is not as fast or powerful as a strong steroid on a thick plaque, and cost, not side effects, is why people do not end up on it.
— Dr. Schwarz, Board Certified Dermatologist
Key Facts
−
| Also called | Zoryve |
| Drug class | Topical PDE4 inhibitor |
| Applied as | 0.3% cream, 0.15% cream, and 0.3% foam |
| Approved for | Plaque psoriasis, mild to moderate eczema, and seborrheic dermatitis. Approved ages differ by form and condition |
| Typical course | Once daily, long term, with no fixed stopping point |
| Time to work | Itch often within a week or two, visible clearing over 4 to 8 weeks |
| Prescription only | Yes |
What It Is
−
Roflumilast is a prescription anti-inflammatory that blocks an enzyme called phosphodiesterase 4, or PDE4. The topical version was approved in the United States in 2022, first as a 0.3% cream for plaque psoriasis in adolescents and adults, and the approved age has since been extended downward. A 0.3% foam was approved later for seborrheic dermatitis, and a lower-strength 0.15% cream for mild to moderate eczema. Ages differ by form and condition, so check which one you have and what it treats. Roflumilast has been a tablet for years in severe chronic obstructive pulmonary disease. The creams and foam deliver the same drug into the skin at doses that avoid most of the stomach and weight side effects that limit the tablet. Brand only. No generic.
How It Works
−
Inside immune cells there is a signaling molecule called cyclic AMP. High cyclic AMP calms the cell and it makes fewer inflammatory signals. PDE4 is the enzyme that breaks cyclic AMP down, which lets the cell stay switched on.
Roflumilast blocks PDE4. Cyclic AMP builds up, the cell turns its own inflammation down, and the output of several inflammatory signals drops at once, including the ones central to psoriasis.
Same target as apremilast, an oral psoriasis tablet, and crisaborole, a milder eczema ointment. Roflumilast binds PDE4 far more tightly than crisaborole, which is why it is more effective.
Because it works through cyclic AMP rather than the steroid receptor, it has no effect on collagen. It does not thin skin, cause stretch marks or visible small blood vessels, or cause a rebound flare. That is why it can go on the face, eyelids, armpits, groin and under the breasts, with no limit on how long you use it.
Here is where Roflumilast Cream (Zoryve) acts in the skin, and what the others do instead.
About Roflumilast Cream (Zoryve)
Compare
Skin basics
The redness, swelling and itch are the immune system reacting, not the damage itself. Roflumilast Cream (Zoryve) turns that reaction down where it is happening, in the skin, which is why a rash settles within days. A stronger PDE4 blocker than crisaborole, once a day, and no steroid. Used for eczema, psoriasis and seborrheic dermatitis.
Roflumilast crosses well and is used once a day for that reason. Enough reaches the blood to be measurable, which is why it is prescription.
In a plaque, skin cells travel from the bottom of the epidermis to the surface in four to six days instead of a month, and pile up as scale. This slows them back down, so the plaque thins.
The outer film of dead cells and oil. It holds water in and keeps irritants out, and it is thinner than a sheet of paper. Almost every dry, itchy, stinging skin problem starts here.
The outer layer, and the only one anything in a jar reaches. It renews itself constantly: a cell made at the bottom takes about a month to reach the surface and flake off. Most of what a skincare product does, it does here.
The living layer underneath, holding the blood vessels, the nerves and the collagen. It is where lasting change happens and it is hard to reach: most of what is sold for the skin never gets this far.
What It Treats
−





Not the Best For
−
Forms
−
Cream, 0.3%:
Cream, 0.15%:
Foam, 0.3%:
All three are applied once a day:
Strengths
−
Two strengths, two bases.
Basics
−
Sample Routine
−
Here is where Roflumilast Cream (Zoryve) sits in a day, and what goes around it. Pick what you are treating and what your skin is like, and the rest of the routine changes to suit.
What to Expect
−
What to Avoid
−
- Applying it more than once a day Twice does not work faster and makes stomach side effects more likely.
- Applying it to infected skin Treat impetigo, cold sores, shingles or a fungal rash first.
- Using it inside the eyes, mouth or vagina On the eyelid skin is fine; in the eye is not. Rinse with water if it gets in.
- Spraying or using the foam near a flame It is flammable until it dries. No smoking while applying it.
- Using it on an undiagnosed rash It calms several kinds of inflammation, so it can mask something that needs different treatment.
- Stopping the moment it looks clear Psoriasis and seborrheic dermatitis keep coming back, and this is one of the few topicals with no reason to stop.
- Heavy alcohol use It makes the loose stools worse.
Monitoring
−
No routine blood tests, no boxed warning, no limit on how much body surface you treat, no maximum duration.
What is worth watching has nothing to do with skin. The oral form causes diarrhea, nausea, appetite loss and weight loss in a meaningful number of people, and has been linked to low mood and, rarely, suicidal thoughts. The cream and foam give much lower blood levels, so these are far less common — but they are on the label and your doctor will ask. If you lose weight without trying, or your mood drops, say so.
Otherwise monitoring is a review of whether it is working, around 8 weeks at first. Your doctor will check your history for liver problems, since severe liver impairment rules it out.
If You Stop
−
No taper, no rebound. You can stop on any day. Unlike strong steroids, stopping does not trigger a flare of its own. The condition returns at its own pace, usually over weeks, because the drug controls inflammation rather than curing the tendency. With no thinning risk and no time limit, most people doing well on it do not stop. Where treatment is reduced, it is usually to every other day or a few times a week.
Cost
−
This is the main reason people do not end up on it. Roflumilast is brand only with no generic, and a tube runs to several hundred dollars or more. Generic steroid creams cost a small fraction of that. A prior authorization is close to routine. Most plans want to see that a topical steroid was tried and either failed or is not appropriate — the fold, face and eyelid argument usually succeeds, because those are exactly the places long-term steroid use causes harm. Some plans also want a vitamin D cream tried first. Denials are common on the first attempt and often overturned on appeal, so push back. The manufacturer runs a copay program that can cut the cost substantially with commercial insurance, plus patient assistance for people who qualify. Terms change often. People on government insurance generally cannot use copay cards, which is a real gap. One practical note: cost is per tube and psoriasis treatment is open-ended, so ask about the largest tube your plan will cover — the price per gram is usually better.
Ask Your Doctor
−
How It Compares
−


Myths
+
- "It is a steroid." It is not. It works through a different pathway and does not thin skin, cause stretch marks, visible small blood vessels or a rebound flare. That is why there is no limit on where or how long you use it.
- "It is the same as the psoriasis tablet." Apremilast is a different drug that blocks the same enzyme. Roflumilast cream produces much lower blood levels than any oral PDE4 tablet, so the stomach effects that limit the tablets matter much less.
- "It will upset my stomach like the COPD tablet." The oral form causes diarrhea and weight loss often enough to be a real problem. With the cream and foam those effects are uncommon and usually mild.
- "Once a day cannot be enough." Once daily is what the trials used and what the label says. Twice speeds nothing up.
- "You have to stop after a few weeks." That rule comes from steroid creams. There is no fixed maximum duration here.
- "The dark or pale patch left behind means it is not working." That is a mark left after the inflammation cleared, not active disease. It fades over months, and shows up more on deeper skin tones.
Questions Patients Ask
+
Is roflumilast a steroid?
No. It blocks an enzyme called PDE4 inside inflammatory cells. It does not thin skin, which is why it can go on the face, eyelids and folds without a time limit.
How long can I use it?
There is no fixed maximum. The rule about stopping after a few weeks comes from steroid creams. Long-term daily use with regular review is normal.
Why is it once a day when most creams are twice?
Once daily is what the trials tested. Twice does not clear skin faster and makes stomach side effects more likely.
Will it upset my stomach?
Usually not. Diarrhea, nausea and headache are listed because they can happen, and are common with the oral version used for lung disease. Blood levels from the cream and foam are much lower.
What is the difference between the cream and the foam?
The drug is the same. The foam lets it spread through hair and over the scalp, and it is the form used for seborrheic dermatitis. The 0.3% cream is for psoriasis and the 0.15% cream for eczema.
Why is there still a mark where the plaque was?
Clearing inflammation often leaves a dark or pale patch. Not active disease, and it fades over months. It shows up more on deeper skin tones.
Can I use it with a steroid cream?
A common approach — a strong steroid for the thickest patches, roflumilast for the face, folds and the rest. Plan it with your doctor rather than layering both on one spot.
References
+
- Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: Guidelines of care for the management of atopic dermatitis in adults. Journal of the American Academy of Dermatology. 2025. — Journal of the American Academy of Dermatology, 2025
- Davis DMR, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology. 2026. — Journal of the American Academy of Dermatology, 2026
- Kow CS, Ramachandram DS, Hasan SS, et al. Efficacy and Safety of Roflumilast Cream in Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. The Australasian journal of dermatology. 2025. — The Australasian journal of dermatology, 2025
- Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials. JAMA dermatology. 2024. — JAMA dermatology, 2024
- Eichenfield LF, Serrao R, Prajapati VH, et al. Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial. Pediatric dermatology. 2025. — Pediatric dermatology, 2025
- Pixley JN, Schaetzle T, Feldman SR. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis. The Annals of pharmacotherapy. 2023. — The Annals of pharmacotherapy, 2023
